For pharmaceutical companies, research and development and sales costs have always been the focus
of market attention.
According to wind data, in the first half of 2022, all pharmaceutical companies listed on the A-share Hong Kong stock market, including Shenwan Pharmaceutical Biology and Shenwan Beauty Care Industry 560 companies, had a total revenue of 1.
7853 trillion yuan in the first half of the year, a total sales expense of 219.
8 billion yuan, and an overall sales expense ratio of about 12.
3%.
It is worth noting that the sales costs of many pharmaceutical companies have shrunk
.
For example, Hengrui Pharmaceutical's sales expenses in the first half of the year were 3.
27 billion yuan, compared with 4.
67 billion yuan in the same period last year, a decrease of 1.
4 billion yuan, a decrease of 30%.
The sales expenses of Chinese traditional Chinese medicines in the first half of the year were 1.
72 billion yuan, compared with 3.
04 billion yuan in the same period last year, a decrease of 1.
33 billion yuan, a decrease of 43%.
The sales expense of Yiling Pharmaceutical in the first half of the year was 1.
48 billion yuan, compared with 2.
05 billion yuan in the same period last year, a decrease of 570 million yuan, a decrease of 27%.
Sinopharm Hyundai's sales expenses in the first half of the year decreased by more than 420 million yuan, and the sales expenses of Buchang Pharmaceutical, Ruikang Pharmaceutical, North China Pharmaceutical and Shanghai Jahwa also decreased by more than 300 million yuan in the first half of the year
.
Industry analysts believe that under the normalization of collection and procurement, the demand for sales by pharmaceutical companies has been greatly reduced, and the transformation of the model of selling drugs with gold in the past is the main reason for the reduction of sales costs of a large number of
pharmaceutical companies.
It is understood that in recent years, with the implementation of policies such as "generic drug consistency evaluation", "procurement with quantity", and "medical insurance negotiation", the pharmaceutical industry is facing huge adjustments
.
In this context, China's innovative pharmaceutical companies are paying more and more attention to the investment in the research and development of innovative drugs, many pharmaceutical companies have reduced sales costs, but the investment in research and development is increasing
.
Data show that in the first half of the year, more than 70% of innovative pharmaceutical companies increased
their R& D investment.
Among them, 7 companies, including BeiGene, Hengrui, Junshi Biological, China Biopharmaceuticals, CSPC Pharmaceutical Research and Development, and Huang Pharmaceutical, have invested more than 1 billion yuan
.
BeiGene's R&D expenditure in the first half of the year exceeded 5 billion yuan to 5.
016 billion yuan, an increase of 20.
82%
compared with the same period last year.
It is reported that the company's R & D investment is used for pre-bed research, clinical trials, cooperative research and development of product pipelines
.
Hengrui Pharmaceutical's cumulative R&D investment in the first half of the year was 2.
909 billion yuan, an increase of 12.
74% year-on-year, and the proportion of R&D investment in sales revenue increased to a record high of 28.
44%
year-on-year.
In addition, Fosun Pharma's R&D investment in the first half of the year reached 2.
399 billion yuan, an increase of 22.
77% year-on-year, of which R&D expenses were 1.
818 billion yuan, an increase of 256 million yuan and an increase of 16.
39%
year-on-year.
It is worth mentioning that at present, under the accelerated innovation of pharmaceutical companies, the income of innovative drugs of many pharmaceutical companies has reached a new high
.
For example, the 2022 semi-annual report released by Simcere Pharmaceutical on August 31 shows that the revenue of innovative drugs in the first half of the year was 1.
767 billion yuan, an increase of 44.
8% year-on-year, accounting for 65.
4%
of the total revenue of 2.
700 billion yuan.
In the first half of the year, the role of innovative drugs in China Biopharmaceuticals became more and more obvious in its performance, with a total revenue of 3.
49 billion yuan, accounting for 22.
9% of the total revenue of 15.
19 billion yuan, an increase of 14.
2%
year-on-year.
The company also expects that the revenue of innovative drugs will account for 24% this year, and the revenue of innovative drugs is expected to exceed 10 billion yuan
by 2023.
In addition, Hexion Pharmaceuticals received revenue from innovative drugs of approximately RMB2.
321 billion in the first half of the year, an increase of approximately 84.
8% year-on-year, accounting for about
52.
3% of the total revenue (RMB4.
434 billion).
From the above point of view, with the improvement of the threshold for innovative research and development, the industry pharmaceutical enterprises that truly have the ability to innovate and have differentiated research and development pipelines are ushering in more and more broad development space
.
